Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS102 plus apatinib for third-line or later HER2-negative gastric or esophagogastric junction adenocarcinoma
ChiCTR2500098779Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Shanxi Medical University
- Start
- Mar 2025
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil and Rivoceranib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by First Affiliated Hospital of Shanxi Medical University. Primary endpoint: Progression-free survival. Planned start Mar 2025; status: not yet recruiting.
02
Drugs
trifluridine + tipiracilRivoceranib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500098779.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098779.